Nordeloz (Zoledronic Acid)

Zoledronic acid binds to bone mineral surfaces and is taken up by osteoclasts, the cells that break down bone. It blocks the enzyme farnesyl pyrophosphate synthase, which is essential for osteoclast function, leading to cell apoptosis and a marked decrease in bone resorption.

The dosing regimen for Nordeloz is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Healthcare professionals follow approved guidelines and adjust the infusion schedule as needed for each individual.

Safety data for zoledronic acid in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians typically avoid prescribing it to pregnant or nursing women unless absolutely necessary.

To place an order, submit an enquiry on the Nordeloz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nordeloz (zoledronic acid) is a highly potent, once‑yearly or once‑every‑few‑months intravenous bisphosphonate, offering greater convenience compared with oral agents that require daily or weekly dosing. Its strong affinity for bone provides sustained inhibition of resorption, but it also carries a higher risk of acute infusion‑related reactions.

Nordeloz should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture and direct sunlight to preserve drug stability until the time of preparation for infusion.

Nordeloz is given as an intravenous infusion over a short period, typically 15 minutes, under the supervision of a qualified healthcare professional. The infusion is performed in a clinical setting where vital signs can be monitored and any acute reactions can be managed promptly.

The most serious adverse events include renal toxicity, severe hypocalcaemia, osteonecrosis of the jaw, and rare cases of anaphylaxis or cardiac arrhythmias such as atrial fibrillation. Patients should be screened for renal impairment and calcium levels before each dose, and dental health should be assessed prior to treatment.

Nordeloz is contraindicated in patients with known hypersensitivity to zoledronic acid or any component of the formulation, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with untreated hypocalcaemia. Caution is also advised for patients with active dental infections or recent oral surgery.